A detailed history of Koss Olinger Consulting, LLC transactions in Abb Vie Inc. stock. As of the latest transaction made, Koss Olinger Consulting, LLC holds 2,166 shares of ABBV stock, worth $421,915. This represents 0.03% of its overall portfolio holdings.

Number of Shares
2,166
Holding current value
$421,915
% of portfolio
0.03%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 06, 2024

BUY
$154.79 - $180.76 $335,275 - $391,526
2,166 New
2,166 $371,000
Q4 2023

Feb 13, 2024

SELL
$137.6 - $154.97 $6,329 - $7,128
-46 Reduced 2.35%
1,912 $296,000
Q3 2023

Oct 10, 2023

BUY
$133.59 - $154.65 $37,405 - $43,302
280 Added 16.69%
1,958 $291,000
Q1 2023

May 12, 2023

SELL
$144.61 - $166.54 $23,282 - $26,812
-161 Reduced 8.75%
1,678 $267,000
Q4 2022

Feb 13, 2023

SELL
$138.31 - $165.87 $90,454 - $108,478
-654 Reduced 26.23%
1,839 $297,000
Q3 2022

Nov 14, 2022

BUY
$134.21 - $153.93 $42,678 - $48,949
318 Added 14.62%
2,493 $335,000
Q2 2022

Jul 08, 2022

SELL
$137.62 - $174.96 $84,773 - $107,775
-616 Reduced 22.07%
2,175 $333,000
Q1 2022

May 06, 2022

SELL
$131.98 - $163.75 $161,939 - $200,921
-1,227 Reduced 30.54%
2,791 $452,000
Q4 2021

Feb 07, 2022

BUY
$107.43 - $135.93 $36,096 - $45,672
336 Added 9.13%
4,018 $544,000
Q3 2021

Nov 09, 2021

SELL
$106.4 - $120.78 $119,274 - $135,394
-1,121 Reduced 23.34%
3,682 $397,000
Q2 2021

Aug 11, 2021

BUY
$105.21 - $117.21 $44,293 - $49,345
421 Added 9.61%
4,803 $541,000
Q1 2021

May 14, 2021

BUY
$102.3 - $112.62 $448,278 - $493,500
4,382 New
4,382 $474,000

Others Institutions Holding ABBV

About AbbVie Inc.


  • Ticker ABBV
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,768,099,968
  • Market Cap $344B
  • Description
  • AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...
More about ABBV
Track This Portfolio

Track Koss Olinger Consulting, LLC Portfolio

Follow Koss Olinger Consulting, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Koss Olinger Consulting, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Koss Olinger Consulting, LLC with notifications on news.